Buprenorphine formulations for intranasal delivery

Details Buprenorphine formulations for intranasal delivery Buprenorphine formulations for intranasal delivery

2002-03-19

2010-02-23

Padmanabhan, Sreeni (Department: 1617)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S054000, C514S453000, C424S434000, C546S044000

Reexamination Certificate

active

07666876

ABSTRACT:
Aqueous formulations suitable for intranasal administration comprise buprenorphine or a physiologically acceptable salt or ester thereof and (a) a pectin having a degree of esterification of less than 50%, (b) chitosan and a polyoxyethylene-polyoxypropylene copolymer (poloxamer) or (c) chitosan and hydroxypropylmethylcellulose. Such formulations can induce rapid and prolonged analgesia when delivered intranasally to a patient. The buprenorphine or buprenorphine salt or ester may be delivered to the bloodstream to produce within 30 minutes a therapeutic plasma concentration of buprenorphine, Cther, of 0.2 ng/ml or greater which is maintained for a duration Tmaintof at least 2 hours.

REFERENCES:
patent: 4981875 (1991-01-01), Leusner et al.
patent: 5147648 (1992-09-01), Bannert
patent: 5456745 (1995-10-01), Roreger et al.
patent: 5508042 (1996-04-01), Oshlack et al.
patent: 6090368 (2000-07-01), Zin et al.
patent: 6387917 (2002-05-01), Illum et al.
patent: 6432440 (2002-08-01), Watts et al.
patent: 6610271 (2003-08-01), Wermeling
patent: 6777000 (2004-08-01), Ni et al.
patent: 2003/0077300 (2003-04-01), Wermeling
patent: 2005/0142072 (2005-06-01), Birch et al.
patent: 2007/0231269 (2007-10-01), Birch et al.
patent: 0 460 020 (1990-09-01), None
patent: 0 571 671 (1993-01-01), None
patent: 0 571 671 (1993-12-01), None
patent: 1 108 423 (2001-06-01), None
patent: 2 378 383 (2003-02-01), None
patent: 7-503481 (1995-04-01), None
patent: 2000-229859 (2000-08-01), None
patent: 2000 229859 (2000-08-01), None
patent: 2001-2589 (2001-01-01), None
patent: 2001-524094 (2001-11-01), None
patent: 82/03768 (1982-11-01), None
patent: WO 87/04350 (1987-07-01), None
patent: WO 88/10121 (1988-12-01), None
patent: 90/09780 (1990-09-01), None
patent: 93/15737 (1993-08-01), None
patent: WO 94/10987 (1994-05-01), None
patent: WO 96/33694 (1996-10-01), None
patent: WO 97/04780 (1997-02-01), None
patent: 98/47535 (1998-10-01), None
patent: WO 98/47535 (1998-10-01), None
patent: 99/09962 (1999-03-01), None
patent: WO 99/13799 (1999-03-01), None
patent: 99/27905 (1999-06-01), None
patent: WO 99/45963 (1999-09-01), None
patent: WO 00/12063 (2000-03-01), None
patent: 01/29046 (2001-04-01), None
patent: 01/035942 (2001-05-01), None
patent: WO 01/58447 (2001-08-01), None
patent: 02/00195 (2002-01-01), None
patent: WO 02/00195 (2002-01-01), None
patent: 02/067897 (2002-09-01), None
patent: WO 03/080022 (2003-10-01), None
Eriksen, J. et al. J. Pharm. Pharmacol. 1989, 41, 803-805.
Reich, I., et al. “Tonicity, Osmoticity, Osmolality and Osmolarity” Remington: The Science and Practice or Pharmacv, Nineteenth Edition, vol. 1. Easton, PA: Mack, 1995. pp. 613-615.
Nairn, J. G. Solutions, Emulsions, Suspensions and Extracts Remington: The Science and Practice or Pharmacv, Nineteenth Edition, vol. 2. Easton, PA: Mack, 1995. p. 1502.
Eriksen et al; “The Systemic Availability of Buprenorphine Administered by Nasal Spray”; J. Pharm. Pharmacol., 1989, 41: 803-805, Apr. 13, 1989.
Cassidy et al; “Controlled Buccal Delivery of Buprenorphine”; Journal of Controlled Release, vol. 25, 1993, pp. 21-29.
Reynolds; Martindale, The Extra Pharmacopoeia, Thirty-first Edition, 1996, pp. 43-45.
Semde et al, “Leaching of pectin from mixed pectin/insoluble polymer films intended for colonic drug delivery”, International Journal of Pharmaceutics 174 (1998) 233-241.
Hussain et al, “Nasal absorption of naloxone and buprenorphine in rats”, International Journal of Pharmaceutics, 21 (1984) 233-237.
International Journal of Pharmaceutics, 129, 1996, 233-239 (Talukdar et al).
International Journal of Pharmaceutics, 217, 2001, 121-126 (Lindhardt et al).
International Journal of Pharmaceutics, 205, 2000, 159-163 (Lindhardt et al).
Merck Index, 13thedition, 2001, Entry 6551.
Verma et al, J. Psychol. Pharmacol., vol. 7, No. 3, pp. 270-275, 1993.
Soane et al, Int. J. Pharm., 178, 55-65, 1999.
Machine English translation of JP 2000-229859 as well as a partial English language translation.

Affiliated with

Also associated with

Rating

Buprenorphine formulations for intranasal delivery does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Buprenorphine formulations for intranasal delivery, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Buprenorphine formulations for intranasal delivery will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4229413